Related Experiment Video
Updated: Aug 15, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Rationale and indications for continuous infusion of antihemophilic factor (factor VIII)
1Alpha Therapeutic Corporation, Los Angeles, CA 90032, USA.
Abstract:
The continuous infusion of drugs and biological compounds, such as factor VIII concentrate, should enhance therapeutic efficacy. Factor VIII can be produced by recombinant DNA technology or derived from plasma. Improvements to the stability of the compound have made continuous infusion feasible. Current and potential applications of continuous infusion of factor VIII product include (1) peri-operative conditions, (2) bleeding that threatens life or limb, (3) primary or secondary Prophylaxis and (4) immune tolerance therapy for factor VIII allo-antibodies. Less use of costly factor VIII and decreased laboratory expenses also contribute to the usefulness of continuous infusion.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Venous Thrombosis III: Interprofessional Care
Continuous Renal Replacement Therapy

